Document Detail


The therapeutic implications of Renin-Angiotensin system blockade in diabetic retinopathy.
MedLine Citation:
PMID:  20939795     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Research has proven that blood pressure is an important modifiable risk factor for diabetic retinopathy and that lowering high blood pressure significantly reduces the development and progression of retinopathy in both type 1 and type 2 diabetic patients. The renin-angiotensin-system (RAS) has been shown to become activated in diabetes. Hyperglycaemia stimulates the angiotensin AT1-receptor and downstream chains of events resulting in diabetic end organ damage. Pharmacological RAS inhibition may thus be a beneficial therapeutic strategy in the management of diabetic retinopathy. The present review article details therapeutic RAS inhibition in diabetic retinopathy with an emphasis on recently published evidence. Future research on the potential effects of RAS blockade will be important while using these drugs as adjuncts in the treatment of diabetic retinopathy.
Authors:
V Swetha Jeganathan
Related Documents :
9783835 - Relationship between contrast sensitivity and metabolic control in diabetics with and w...
2738945 - Correlation between macrovascular disease as assessed by bioimpedance plethysmography a...
3253135 - Blindness in the city of nottingham (1980-1985).
7196565 - The effects of panretinal photocoagulation on dark adaptation in diabetics with prolife...
2863015 - The half-life of endogenous insulin and c-peptide in man assessed by somatostatin suppr...
2180315 - Impaired insulin action but normal insulin receptor activity in diabetic rat liver: eff...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  12     ISSN:  1873-4316     ISO Abbreviation:  Curr Pharm Biotechnol     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  392-5     Citation Subset:  IM    
Affiliation:
Tun Hussein Onn National Eye Hospital, Lorong Utara B, 46200 Petaling Jaya, Selangor Darul Ehsan, Malaysia. vswetha@ausdoctors.net.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.
Next Document:  Protein kinase C inhibitors in the treatment of diabetic retinopathy. Review.